EUVIMEDEUVIMED entdecken
Open Access

Prostate Cancer Screening and Likelihood of Benefit in Veterans Affairs and Fee-for-Service Medicare

Alex K Bryant, Adam VanDeusen, Mandi L Klamerus, Brent S Rose, Krithika Suresh, Timothy P Hofer, Sameer D Saini, Tanner J Caverly

JAMA Internal Medicine · 01.11.2026 · 186 (11) · 1391

DOI: 10.1001/jamainternmed.2026.4660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.11.2026. Verfasst von Alex K Bryant und 7 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Fee-for-Service Plans, Prostate-Specific Antigen, Medicare. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: ORD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Routine prostate-specific antigen (PSA) screening in men with limited life expectancy is low-value care, yet US Department of Veterans Affairs (VA) PSA testing and biopsy rates have not been benchmarked against non-VA care.

Objective

To determine whether PSA testing and prostate biopsy rates are associated with likelihood of benefit from screening in VA or fee-for-service (FFS) Medicare primary care. Design, Setting, and Participants This retrospective cohort study used national linked VA-Medicare data for fiscal years 2004 to 2023, with up to 20 years of follow up. A 30% random sample of male veterans 65 years or older who were dually enrolled in VA and FFS Medicare Parts A and B were included; men with prior prostate cancer or only Medicare Advantage enrollment were excluded. Exposures Time-varying predominant primary care setting (VA, FFS Medicare, or dual use), assigned from primary care visit distribution across systems over a rolling 36-month window. Main Outcomes and Measures PSA testing and prostate biopsy rates per 1000 person-years. Contemporary incidence rate ratios (IRRs) were estimated with covariate-adjusted Poisson regression and stratified by age and predicted life expectancy.

Results

Among 1.41 million dually enrolled male veterans (mean [SD] age, 71.3 [7.1] years), 8.67 million person-years were observed. PSA testing declined across settings from 2008 to 2017, with steeper declines in the VA system. From 2018 to 2023, among men 80 years or older, adjusted PSA testing rates were 187.9 vs 267.9 per 1000 person-years in VA primary care vs FFS Medicare (IRR, 0.70; 95% CI, 0.69-0.71), and biopsy rates were 3.38 vs 5.05 (IRR, 0.67; 95% CI, 0.60-0.75). Among men with fewer than 5 years predicted life expectancy, PSA testing in the VA setting was lower (IRR, 0.84; 95% CI, 0.82-0.86). Age- and life expectancy–based differences persisted across sensitivity analyses. In contrast, in the primary analysis, PSA testing in the VA setting was higher among men aged 65 to 69 years (IRR, 1.10; 95% CI, 1.09-1.11). Conclusions and Relevance In this cohort study, compared with FFS Medicare, VA primary care was associated with lower PSA testing and biopsy rates among veterans least likely to benefit, suggesting closer alignment of testing intensity with likelihood of benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsFee-for-Service PlansProstate-Specific AntigenMedicareEarly Detection of CancerMaleHumansUnited StatesAgedRetrospective StudiesUnited States Department of Veterans AffairsBiopsyPrimary Health CareAged, 80 and overVeterans

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Veterans Affairs Center for Clinical Management Research, Ann Arbor, Michigan.
  • Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan.
  • Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor.
  • Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor.
  • Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor.
  • Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, La Jolla.

Förderung

  • ORD VA

Zitieren

APA

Bryant, A. K., VanDeusen, A., Klamerus, M. L., Rose, B. S., Suresh, K., Hofer, T. P., Saini, S. D., & Caverly, T. J. (2026). Prostate Cancer Screening and Likelihood of Benefit in Veterans Affairs and Fee-for-Service Medicare. JAMA Internal Medicine, 186(11), 1391. https://doi.org/10.1001/jamainternmed.2026.4660

Vancouver

Bryant AK, VanDeusen A, Klamerus ML, Rose BS, Suresh K, Hofer TP, et al. Prostate Cancer Screening and Likelihood of Benefit in Veterans Affairs and Fee-for-Service Medicare. JAMA Internal Medicine. 2026;186(11):1391. doi:10.1001/jamainternmed.2026.4660

BibTeX
@article{Bryant2026,
  author = {Bryant, Alex K and VanDeusen, Adam and Klamerus, Mandi L and Rose, Brent S and Suresh, Krithika and Hofer, Timothy P and Saini, Sameer D and Caverly, Tanner J},
  title = {Prostate Cancer Screening and Likelihood of Benefit in Veterans Affairs and Fee-for-Service Medicare},
  journal = {JAMA Internal Medicine},
  year = {2026},
  volume = {186},
  number = {11},
  pages = {1391},
  doi = {10.1001/jamainternmed.2026.4660}
}
Kostenlos starten →